Announcements Trials
Browse Landscape

Phase

Phase 1 7Phase 2 3Phase 3 2Phase EARLY_PHASE1 1Phase 4 1Phase 1/2 1

Status

Active not recruiting 3

Sponsor Class

INDUSTRY 3OTHER 2

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 2NET 1Gastrointestinal 1Endocrine 1CNS 1

Conditions

Prostatic Neoplasms 1Pheochromocytoma 1Paraganglioma 1Metastatic Castration Resistant Prostate Cancer (mCRPC) 1Gastro-enteropancreatic neuroendocrine tumor 1

Interventions

Carboplatin 273Paclitaxel 267Gemcitabine 244Bevacizumab 226Cisplatin 218pembrolizumab 214Docetaxel 210Pemetrexed 162Capecitabine 148Fluorouracil 129Oxaliplatin 121Cyclophosphamide 121Nivolumab 112Dexamethasone 100Trastuzumab 89Leucovorin 87Cetuximab 85Rituximab 83Irinotecan 82Injections 81Erlotinib Hydrochloride 70Prednisone 68Doxorubicin 68Temozolomide 67atezolizumab 65Bortezomib 65Ipilimumab 64Fulvestrant 59Radiotherapy 54Drug Therapy 51

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × INDUSTRY × Lutetium × Clear all
NCT05849298 2026-05-27

PSMACare

Novartis

Phase 2 Active not recruiting
49 enrolled
Genitourinary

Prostatic Neoplasms

NCT06894511 2026-05-01

PSMAndARPI

Novartis

Phase 2 Active not recruiting
7 enrolled
Genitourinary

Metastatic Castration Resistant Prostate Cancer (mCRPC)

NCT04711135 2026-02-12

NETTER-P

Advanced Accelerator Applications

Phase 2 Active not recruiting
11 enrolled 14 charts 1 FDA
CNSEndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Paraganglioma, Pheochromocytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡